Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Menopause-Related Vasomotor Symptoms Market

ID: MRFR/Pharma/66574-CR
100 Pages
Snehal Singh
Last Updated: May 20, 2026

Menopause-Related Vasomotor Symptoms Market Research Report: Information by Treatment Type (Hormone Therapy, Non-Hormonal Treatment and Dietary Supplements), By Menopause Stage (Premature Menopause, Perimenopause and Post-menopause), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channels) By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Menopause-Related Vasomotor Symptoms Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 EXECUTIVE SUMMARY
  2. 2 MARKET INTRODUCTION
    1. 2.1 DEFINITION
    2. 2.2 SCOPE OF THE STUDY
    3. 2.3 RESEARCH OBJECTIVE
    4. 2.4 MARKET STRUCTURE
  3. 3 RESEARCH METHODOLOGY
    1. 3.1 OVERVIEW
    2. 3.2 DATA FLOW
      1. 3.2.1 Data Mining Process
    3. 3.3 PURCHASED DATABASE:
    4. 3.4 SECONDARY SOURCES:
      1. 3.4.1 Secondary Research data flow:
    5. 3.5 PRIMARY RESEARCH:
      1. 3.5.1 Primary Research Data Flow:
      2. 3.5.2 Primary Research: Number of Interviews conducted
      3. 3.5.3 Primary Research: Regional Coverage
    6. 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
      1. 3.6.1 Revenue Analysis Approach
    7. 3.7 DATA FORECASTING
      1. 3.7.1 Data forecasting Type
    8. 3.8 DATA MODELING
      1. 3.8.1 microeconomic factor analysis:
      2. 3.8.2 Data modeling:
    9. 3.9 TEAMS AND ANALYST CONTRIBUTION
  4. 4 MARKET DYNAMICS
    1. 4.1 INTRODUCTION
    2. 4.2 DRIVERS
      1. 4.2.1 Rising Global Menopausal Population & Aging Female Population
      2. 4.2.2 High Prevalence of Vasomotor Symptoms
      3. 4.2.3 Approval & Launch of Novel Non-Hormonal Neurokinin Receptor Antagonists
      4. 4.2.4 Strong Clinical Effectiveness of Hormone Therapy
    3. 4.3 RESTRAINTS
      1. 4.3.1 High Cost of Novel and Advanced Treatments
      2. 4.3.2 Safety Concerns and Patient Hesitancy Around Hormone Therapy
      3. 4.3.3 Underdiagnosis and Stigma Around Menopause
    4. 4.4 OPPORTUNITIES
      1. 4.4.1 Development and Expansion of Novel Neurokinin (NK3) Receptor Antagonists
      2. 4.4.2 Female-Focused & Customized Solutions
  5. 5 MARKET DYNAMICS
    1. 5.1 REGULATORY ENVIRONMENT & COMPLIANCE
    2. 5.2 TECHNOLOGICAL TRENDS & INNOVATION
    3. 5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS
    4. 5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS
      1. 5.4.1 North America
      2. 5.4.2 europe
      3. 5.4.3 asia pacific
      4. 5.4.4 rest of the world
      5. 5.4.5 reimbursement dynamics
    5. 5.5 MARKET ENTRY & EXIT BARRIERS
      1. 5.5.1 Barriers to Entry
      2. 5.5.2 Barriers to exit
    6. 5.6 PARTNERSHIPS & COLLABORATIONS
    7. 5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES
      1. 5.7.1 Consumer Preferences
      2. 5.7.2 HEALTHCARE PROVIDER Preferences
    8. 5.8 PESTLE ANALYSIS
      1. 5.8.1 POLITICAL FACTORS
      2. 5.8.2 Economic FACTORS
      3. 5.8.3 SOCIAL FACTORS
      4. 5.8.4 TECHNOLOGICAL FACTORS
      5. 5.8.5 LEGAL FACTORS
      6. 5.8.6 ENVIRONMENTAL FACTORS
    9. 5.9 PORTER'S FIVE FORCES MODEL
      1. 5.9.1 Threat of New Entrants
      2. 5.9.2 BARGAINING POWER OF SUPPLIERS
      3. 5.9.3 Threat of Substitutes
      4. 5.9.4 Bargaining Power of Buyers
      5. 5.9.5 Intensity of Rivalry
    10. 5.10 PRODUCT PIPELINE ANALYSIS
    11. 5.11 CASE STUDY ANALYSIS
    12. 5.12 INVESTMENT & FUNDING SCENARIOS
    13. 5.13 POST-MARKET SURVEILLANCE & SAFETY DATA
    14. 5.14 DISEASE OVERVIEW
    15. 5.15 DIAGNOSIS
    16. 5.16 CURRENT TREATMENT
  6. 6 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT
    1. 6.1 OVERVIEW
  7. 7 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE
    1. 7.1 OVERVIEW
  8. 8 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL
    1. 8.1 OVERVIEW
    2. Sources: Mrfr Analysis
  9. 9 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY REGION
    1. 9.1 OVERVIEW
    2. 9.2 NORTH AMERICA
      1. 9.2.1 U.S.
      2. 9.2.2 Canada
    3. 9.3 EUROPE
      1. 9.3.1 germany
      2. 9.3.2 UK
      3. 9.3.3 france
      4. 9.3.4 netherlands
      5. 9.3.5 italy
      6. 9.3.6 spain
      7. 9.3.7 Rest of Europe
    4. 9.4 ASIA PACIFIC
      1. 9.4.1 China
      2. 9.4.2 india
      3. 9.4.3 japan
      4. 9.4.4 south korea
      5. 9.4.5 Malaysia
      6. 9.4.6 thailand
      7. 9.4.7 indonesia
      8. 9.4.8 rest of asia pacific
    5. 9.5 LATIN AMERICA
      1. 9.5.1 Brazil
      2. 9.5.2 Mexico
      3. 9.5.3 Argentina
      4. 9.5.4 Rest of Latin America
    6. 9.6 MIDDLE EAST AND AFRICA
      1. 9.6.1 GCC Countries
      2. 9.6.2 South Africa
      3. 9.6.3 Rest of Middle East and Africa
  10. 10 COMPETITIVE LANDSCAPE
    1. 10.1 INTRODUCTION
    2. 10.2 MARKET SHARE ANALYSIS, 2025
    3. 10.3 COMPETITOR DASHBOARD
    4. 10.4 PUBLIC PLAYERS STOCK SUMMARY
    5. 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
    6. 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
      1. 10.6.1 Product Launch
      2. 10.6.2 Relaunch
      3. 10.6.3 Regulatory Approval
      4. 10.6.4 Acquisition
  11. 11 COMPANY PROFILES
    1. 11.1 CIPLA
      1. 11.1.1 COMPANY OVERVIEW
      2. 11.1.2 FINANCIAL OVERVIEW
      3. 11.1.3 Products OFFERed
      4. 11.1.4 KEY DEVELOPMENTS
      5. 11.1.5 SWOT ANALYSIS
      6. 11.1.6 KEY STRATEGIES
    2. 11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      1. 11.2.1 COMPANY OVERVIEW
      2. 11.2.2 FINANCIAL OVERVIEW
      3. 11.2.3 Products OFFERed
      4. 11.2.4 KEY DEVELOPMENTS
      5. 11.2.5 SWOT ANALYSIS
    3. 11.3 PFIZER INC.
      1. 11.3.1 COMPANY OVERVIEW
      2. 11.3.2 FINANCIAL OVERVIEW
      3. 11.3.3 PRODUCTS OFFERED
      4. 11.3.4 KEY DEVELOPMENTS
      5. 11.3.5 SWOT ANALYSIS
      6. 11.3.6 KEY STRATEGIES
    4. 11.4 BAYER AG
      1. 11.4.1 COMPANY OVERVIEW
      2. 11.4.2 FINANCIAL OVERVIEW
      3. 11.4.3 productS OFFERED
      4. 11.4.4 KEY DEVELOPMENTS
      5. 11.4.5 SWOT ANALYSIS
      6. 11.4.6 KEY STRATEGIES
    5. 11.5 THERAMEX
      1. 11.5.1 COMPANY OVERVIEW
      2. 11.5.2 FINANCIAL OVERVIEW
      3. 11.5.3 PRODUCTS OFFERED
      4. 11.5.4 KEY DEVELOPMENTS
      5. 11.5.5 KEY STRATEGIES
    6. 11.6 BESINS HEALTHCARE
      1. 11.6.1 COMPANY OVERVIEW
      2. 11.6.2 FINANCIAL OVERVIEW
      3. 11.6.3 PRODUCTS OFFERED
      4. 11.6.4 KEY DEVELOPMENTS
      5. 11.6.5 KEY STRATEGIES
    7. 11.7 ASTELLAS PHARMA INC.
      1. 11.7.1 COMPANY OVERVIEW
      2. 11.7.2 FINANCIAL OVERVIEW
      3. 11.7.3 PRODUCTS OFFERED
      4. 11.7.4 KEY DEVELOPMENTS
      5. 11.7.5 KEY STRATEGIES
      6. 11.7.6 KEY STRATEGIES
    8. 11.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
      1. 11.8.1 COMPANY OVERVIEW
      2. 11.8.2 FINANCIAL OVERVIEW
      3. 11.8.3 productS OFFERED
      4. 11.8.4 KEY DEVELOPMENTS
      5. 11.8.5 KEY STRATEGIES
    9. 11.9 ZYDUS GROUP
      1. 11.9.1 COMPANY OVERVIEW
      2. 11.9.2 FINANCIAL OVERVIEW
      3. 11.9.3 Products OFFERed
      4. 11.9.4 KEY DEVELOPMENTS
      5. 11.9.5 SWOT ANALYSIS
      6. 11.9.6 KEY STRATEGIES
    10. 11.10 HIKMA PHARMACEUTICALS PLC
      1. 11.10.1 COMPANY OVERVIEW
      2. 11.10.2 FINANCIAL OVERVIEW
      3. 11.10.3 Products OFFERed
      4. 11.10.4 KEY DEVELOPMENTS
      5. 11.10.5 KEY STRATEGIES
    11. 11.11 DATA CITATIONS
    12.  
  12. LIST OF TABLES
  13. TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  14. TABLE 2 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT
  15. TABLE 3 EUROPE PRICING ANALYSIS, BY PRODUCT
  16. TABLE 4 ASIA PACIFIC PRICING ANALYSIS, BY PRODUCT
  17. TABLE 5 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT
  18. TABLE 6 PRODUCT PIPELINE
  19. TABLE 7 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  20. TABLE 8 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  21. TABLE 9 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  22. TABLE 10 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  23. TABLE 11 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  24. TABLE 12 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY REGION, 2019-2036 (USD MILLION)
  25. TABLE 13 NORTH AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  26. TABLE 14 NORTH AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  27. TABLE 15 NORTH AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  28. TABLE 16 NORTH AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  29. TABLE 17 NORTH AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  30. TABLE 18 NORTH AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  31. TABLE 19 U.S. MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  32. TABLE 20 U.S. MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  33. TABLE 21 U.S. MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  34. TABLE 22 U.S. MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  35. TABLE 23 U.S. MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  36. TABLE 24 CANADA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  37. TABLE 25 CANADA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  38. TABLE 26 CANADA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  39. TABLE 27 CANADA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  40. TABLE 28 CANADA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  41. TABLE 29 EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  42. TABLE 30 EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  43. TABLE 31 EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  44. TABLE 32 EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  45. TABLE 33 EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  46. TABLE 34 EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  47. TABLE 35 GERMANY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  48. TABLE 36 GERMANY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  49. TABLE 37 GERMANY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  50. TABLE 38 GERMANY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  51. TABLE 39 GERMANY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  52. TABLE 40 UK MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  53. TABLE 41 UK MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  54. TABLE 42 UK MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  55. TABLE 43 UK MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  56. TABLE 44 UK MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  57. TABLE 45 FRANCE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  58. TABLE 46 FRANCE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  59. TABLE 47 FRANCE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  60. TABLE 48 FRANCE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  61. TABLE 49 FRANCE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  62. TABLE 50 NETHERLANDS MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  63. TABLE 51 NETHERLANDS MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  64. TABLE 52 NETHERLANDS MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  65. TABLE 53 NETHERLANDS MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  66. TABLE 54 NETHERLANDS MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  67. TABLE 55 ITALY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  68. TABLE 56 ITALY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  69. TABLE 57 ITALY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  70. TABLE 58 ITALY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  71. TABLE 59 ITALY MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  72. TABLE 60 SPAIN MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  73. TABLE 61 SPAIN MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  74. TABLE 62 SPAIN MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  75. TABLE 63 SPAIN MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  76. TABLE 64 SPAIN MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  77. TABLE 65 REST OF EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  78. TABLE 66 REST OF EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  79. TABLE 67 REST OF EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  80. TABLE 68 REST OF EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  81. TABLE 69 REST OF EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  82. TABLE 70 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY COUNTRY, 2019-2036 (USD MILLION)
  83. TABLE 71 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  84. TABLE 72 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  85. TABLE 73 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  86. TABLE 74 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  87. TABLE 75 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  88. TABLE 76 CHINA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  89. TABLE 77 CHINA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  90. TABLE 78 CHINA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  91. TABLE 79 CHINA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  92. TABLE 80 CHINA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  93. TABLE 81 INDIA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  94. TABLE 82 INDIA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  95. TABLE 83 INDIA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  96. TABLE 84 INDIA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  97. TABLE 85 INDIA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  98. TABLE 86 JAPAN MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  99. TABLE 87 JAPAN MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  100. TABLE 88 JAPAN MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  101. TABLE 89 JAPAN MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  102. TABLE 90 JAPAN MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  103. TABLE 91 SOUTH KOREA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  104. TABLE 92 SOUTH KOREA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  105. TABLE 93 SOUTH KOREA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  106. TABLE 94 SOUTH KOREA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  107. TABLE 95 SOUTH KOREA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  108. TABLE 96 MALAYSIA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  109. TABLE 97 MALAYSIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  110. TABLE 98 MALAYSIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  111. TABLE 99 MALAYSIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  112. TABLE 100 MALAYSIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  113. TABLE 101 THAILAND MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  114. TABLE 102 THAILAND MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  115. TABLE 103 THAILAND MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  116. TABLE 104 THAILAND MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  117. TABLE 105 THAILAND MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  118. TABLE 106 INDONESIA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  119. TABLE 107 INDONESIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  120. TABLE 108 INDONESIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  121. TABLE 109 INDONESIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  122. TABLE 110 INDONESIA MENOPAUSE -RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  123. TABLE 111 REST OF ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2019-2035 (USD MILLION)
  124. TABLE 112 REST OF ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY HARMONE THERAPY, 2019-2035 (USD MILLION)
  125. TABLE 113 REST OF ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY NON-HARMONE THERAPY, 2019-2035 (USD MILLION)
  126. TABLE 114 REST OF ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  127. TABLE 115 REST OF ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  128. TABLE 116 LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  129. TABLE 117 LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  130. TABLE 118 LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  131. TABLE 119 LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  132. TABLE 120 LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  133. TABLE 121 LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  134. TABLE 122 BRAZIL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  135. TABLE 123 BRAZIL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  136. TABLE 124 BRAZIL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  137. TABLE 125 BRAZIL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  138. TABLE 126 BRAZIL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  139. TABLE 127 MEXICO MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  140. TABLE 128 MEXICO MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  141. TABLE 129 MEXICO MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  142. TABLE 130 MEXICO MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  143. TABLE 131 MEXICO MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  144. TABLE 132 ARGENTINA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  145. TABLE 133 ARGENTINA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  146. TABLE 134 ARGENTINA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  147. TABLE 135 ARGENTINA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  148. TABLE 136 ARGENTINA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  149. TABLE 137 REST OF LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  150. TABLE 138 REST OF LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  151. TABLE 139 REST OF LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  152. TABLE 140 REST OF LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  153. TABLE 141 REST OF LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  154. TABLE 142 MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
  155. TABLE 143 MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  156. TABLE 144 MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  157. TABLE 145 MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  158. TABLE 146 MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  159. TABLE 147 MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  160. TABLE 148 GCC COUNTRIES MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  161. TABLE 149 GCC COUNTRIES MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  162. TABLE 150 GCC COUNTRIES MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  163. TABLE 151 GCC COUNTRIES MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  164. TABLE 152 GCC COUNTRIES MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  165. TABLE 153 SOUTH AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  166. TABLE 154 SOUTH AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  167. TABLE 155 SOUTH AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  168. TABLE 156 SOUTH AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  169. TABLE 157 SOUTH AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  170. TABLE 158 REST OF MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION)
  171. TABLE 159 REST OF MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR HORMONE THERAPY, 2019-2035 (USD MILLION)
  172. TABLE 160 REST OF MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR NON-HORMONAL THERAPY, 2019-2035 (USD MILLION)
  173. TABLE 161 REST OF MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, FOR MENOPAUSE STAGE, 2019-2035 (USD MILLION)
  174. TABLE 162 REST OF MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
  175. TABLE 163 PRODUCT LAUNCH
  176. TABLE 164 RELAUNCH
  177. TABLE 165 REGULATORY APPROVAL
  178. TABLE 166 ACQUISITION
  179. TABLE 167 CIPLA: PRODUCTS OFFERED
  180. TABLE 168 CIPLA: KEY DEVELOPMENT
  181. TABLE 169 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
  182. TABLE 170 PFIZER INC.: PRODUCTS OFFERED
  183. TABLE 171 PFIZER INC.: KEY DEVELOPMENTS
  184. TABLE 172 BAYER AG: PRODUCT OFFERED
  185. TABLE 173 BAYER AG: KEY DEVELOPMENTS
  186. TABLE 174 THERAMEX: PRODUCTS OFFERED
  187. TABLE 175 THERAMEX: KEY DEVELOPMENTS
  188. TABLE 176 BESINS HEALTHCARE: PRODUCTS OFFERED
  189. TABLE 177 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
  190. TABLE 178 ASTELLAS PHARMA INC.: KEY DEVELOPMENTS
  191. TABLE 179 SUN PHARMACEUTICAL INDUSTRIES LTD. : PRODUCT OFFERED
  192. TABLE 180 ZYDUS GROUP: PRODUCTS OFFERED
  193. TABLE 181 HIKMA PHARMACEUTICALS PLC: PRODUCTS OFFERED
  194. TABLE 182 HIKMA PHARMACEUTICALS PLC: KEY DEVELOPMENT
  195. LIST OF FIGURES
  196. FIGURE 1 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET: STRUCTURE
  197. FIGURE 2 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2036)
  198. FIGURE 3 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET DRIVER: IMPACT ANALYSIS
  199. FIGURE 4 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET RESTRAINT: IMPACT ANALYSIS
  200. FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET
  201. FIGURE 6 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, TREATMENT SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION)
  202. FIGURE 7 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY TREATMENT, 2025 & 2035 (USD MILLION)
  203. FIGURE 8 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET SHARE (%), BY TREATMENT, 2025
  204. FIGURE 9 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, MENOPAUSE STAGE SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION)
  205. FIGURE 10 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY MENOPAUSE STAGE, 2025 & 2035 (USD MILLION)
  206. FIGURE 11 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET SHARE (%), BY MENOPAUSE STAGE, 2025
  207. FIGURE 12 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION)
  208. FIGURE 13 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY DISTRIBUTION CHANNEL, 2025 & 2035 (USD MILLION)
  209. FIGURE 14 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2025
  210. FIGURE 15 GLOBAL MARKET ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, 2019-2036 (USD MILLION)
  211. FIGURE 16 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY REGION, 2025 (% SHARE)
  212. FIGURE 17 NORTH AMERICA ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, 2019-2035 (USD MILLION)
  213. FIGURE 18 NORTH AMERICA MARKET ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, 2019-2035 (USD MILLION)
  214. FIGURE 19 NORTH AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION)
  215. FIGURE 20 EUROPE ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, 2019-2035 (USD MILLION)
  216. FIGURE 21 EUROPE MARKET ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, 2019-2035 (USD MILLION)
  217. FIGURE 22 EUROPE MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION)
  218. FIGURE 23 ASIA PACIFIC: SWOT ANALYSIS
  219. FIGURE 24 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, BY REGION, 2025 & 2036 (USD MILLION)
  220. FIGURE 25 ASIA PACIFIC MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET SHARE (%), BY COUNTRY, 2025
  221. FIGURE 26 LATIN AMERICA ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, 2019-2035 (USD MILLION)
  222. FIGURE 27 LATIN AMERICA MARKET ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, 2019-2035 (USD MILLION)
  223. FIGURE 28 LATIN AMERICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION)
  224. FIGURE 29 MIDDLE EAST AND AFRICA ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET, 2019-2035 (USD MILLION)
  225. FIGURE 30 LATIN AMERICA MARKET ANALYSIS: MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, 2019-2035 (USD MILLION)
  226. FIGURE 31 MIDDLE EAST AND AFRICA MENOPAUSE-RELATED VASOMOTOR SYMPTOMS TREATMENT MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION)
  227. FIGURE 32 GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025
  228. FIGURE 33 COMPETITOR DASHBOARD: GLOBAL MENOPAUSE-RELATED VASOMOTOR SYMPTOMS MARKET
  229. FIGURE 34 CIPLA: FINANCIAL OVERVIEW SNAPSHOT
  230. FIGURE 35 CIPLA: SWOT ANALYSIS
  231. FIGURE 36 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  232. FIGURE 37 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
  233. FIGURE 38 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
  234. FIGURE 39 PFIZER INC.: SWOT ANALYSIS
  235. FIGURE 40 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
  236. FIGURE 41 BAYER AG: SWOT ANALYSIS
  237. FIGURE 42 ASTELLAS PHARMA INC.: FINANCIAL OVERVIEW SNAPSHOT
  238. FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  239. FIGURE 44 ZYDUS GROUP: FINANCIAL OVERVIEW SNAPSHOT
  240. FIGURE 45 ZYDUS GROUP: SWOT ANALYSIS
  241. FIGURE 46 HIKMA PHARMACEUTICALS PLC: FINANCIAL OVERVIEW SNAPSHOT

Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)

  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements

Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)

  • Premature Menopause
  • Perimenopause
  • Postmenopause

Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels

Menopause-Related Vasomotor Symptoms Market Regional Outlook (USD Million, 2019-2035)

  • North America Outlook (USD Million, 2019-2035)
  • North America Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • North America Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • North America Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • US Outlook (USD Million, 2019-2035)
  • US Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • US Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • US Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Canada Outlook (USD Million, 2019-2035)
  • Canada Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Canada Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Canada Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
  • Europe Outlook (USD Million, 2019-2035)
  • Europe Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Europe Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Europe Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • GermanyOutlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • UK Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • France Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Russia Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Italy Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Spain Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Rest Of Europe Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels     
  • Asia-Pacific Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • China Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • India Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Japan Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • South Korea Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Rest of Asia-Pacific Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
  • South America Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Brazil Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Mexico Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Argentina Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Rest of South America Outlook (USD Million, 2019-2035)
  • Rest of South America Germanium-68 Gallium-68 Generator Market by Product type Outlook (USD Million, 2019-2035)
  • Column Generators
  • Automated Generator Systems
  • Rest of South America Germanium-68 Gallium-68 Generator Market by Production Method Outlook (USD Million, 2019-2035)
  • Cyclotron-Based Production
  • Nuclear Reactor-Based Production
  • Rest of South America Germanium-68 Gallium-68 Generator Market by Application Outlook (USD Million, 2019-2035)
  • Positron Emission Tomography
  • Radiopharmaceutical Manufacturing
  • Research Activities
  • Rest of South America Germanium-68 Gallium-68 Generator Market by Capacity Outlook (USD Million, 2019-2035)
  • High Capacity
  • Low Capacity
  • Medium Capacity
  • North America Germanium-68 Gallium-68 Generator Market by Indication Outlook (USD Million, 2019-2035)
  • Neuroendocrine Tumors
  • Prostate Cancer
  • Infection & Inflammation
  • Others
  • Rest of South America Germanium-68 Gallium-68 Generator Market by End-User Outlook (USD Million, 2019-2035)
  • Hospitals
  • Independent Radiotherapy Centers
  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Rest of South America Germanium-68 Gallium-68 Generator Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Direct Sales
  • Distributors
  • Middle East & Africa Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • GCC Countries Outlook (USD Million, 2019-2035)
  • Global Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Global Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Global Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • South Africa Outlook (USD Million, 2019-2035)
  • South Africa Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • South Africa Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • South Africa Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
    • Rest of Middle East & Africa Outlook (USD Million, 2019-2035)
  • Rest of Middle East & Africa Menopause-Related Vasomotor Symptoms Market by Treatment Type Outlook (USD Million, 2019-2035)
  • Hormone Therapy
  • Non-Hormonal Therapy
  • Dietary Supplements
  • Rest of Middle East & Africa Menopause-Related Vasomotor Symptoms Market by Menopause Stage Outlook (USD Million, 2019-2035)
  • Premature Menopause
  • Perimenopause
  • Postmenopause
  • Rest of Middle East & Africa Menopause-Related Vasomotor Symptoms Market by Distribution Channel Outlook (USD Million, 2019-2035)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓